The board of directors of Beijing Tong Ren Tang Chinese Medicine Company Limited announced that with effect from 19 April 2023, Mr. Chen Fei was re-designated from the chief executive officer of the Company to the executive deputy general manager of the Company, whilst continuing with his present role as an executive Director and a member of the competition executive committee of the Company. The Board further announces that Mr. Yu Jin has been appointed as the chief executive officer of the Company with effect from 19 April 2023. Yu Jin, aged 53, has more than 30 years of experience in medical and pharmaceutical industry.

Mr. Yu was an assistant to the chairman of the board of directors in Tianda Pharmaceuticals Limited from 2022 to February 2023 and served as the managing director in Beiyu Medical Device (Shanghai) Co. Ltd. from 2016 to 2022. Mr. Yu held senior positions such as a general manager of the PRC region in different well-known multinational medical and pharmaceutical companies, including Abbott's Diabetes Care Division, Johnson & Johnson Vision, Gambro and BSN Medical.

Mr. Yu obtained a bachelor's degree in industrial foreign trading from Guangdong Institute of Technology (now known as Guangdong University of Technology) in 1991 and obtained EMBA degree from China Europe International Business School in 2011. The term of appointment of Mr. Yu as chief executive officer of the Company is 3 years (with 1 year probation). Mr. Yu's emolument before tax is RMB2,200,000 per annum (including basic salary and a performance bonus), which is determined by the Board upon the recommendation of the remuneration committee of the Company by reference to his duties and responsibilities in the Company and the Company's remuneration policy.